Neuropathy in Human Immunodeficiency Virus: A Review of the Underlying Pathogenesis and Treatment

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2022 Jul 18

PMID 35844323

Authors

Lakshya Motwani

Nailah Asif

Apurva Patel

Deepanjali Vedantam

Devyani S Poman

Affiliations

Soon will be listed here.

Abstract

This article explores the various causes of the human immunodeficiency virus (HIV), and its associated neuropathy, including the effects of HIV on the nervous system and the long-standing therapy that is often provided to patients with HIV. Several studies regarding the neurotoxic effects of combined antiretroviral therapy (cART) and HIV were reviewed and various hypotheses were discussed. Furthermore, we present the nature of HIV-sensory neuropathy (HIV-SN) among different demographic populations and their subsequent risk factors predisposing them to this condition. It was observed that the incidence of the disease increases in increased survival of the patients as well as in males. Finally, the current approach to HIV-SN and its overlapping features with other causes of peripheral neuropathy have been discussed which demonstrates that a clinical examination is the most important clue for a healthcare professional to suspect the disease. Our main aim was to study the current perspectives and guidelines for diagnosing and managing a patient with HIV-SN to reduce disease prevalence and bring about a more aware frame of mind when following up with an HIV patient.

Citing Articles

Developing an HIV-specific falls risk prediction model with a novel clinical index: a systematic review and meta-analysis method.

Ibeneme S, Odoh E, Martins N, Ibeneme G BMC Infect Dis. 2024; 24(1):1402.

PMID: 39696054 PMC: 11653889. DOI: 10.1186/s12879-024-10141-5.

The association of sociodemographic characteristics and comorbidities with post-acute sequelae of SARS-CoV-2 in a Medicaid managed care population with and without HIV.

Wu Y, Mattas E, Brandenburg C, Fusaris E, Overbey R, Ernst J PLoS One. 2024; 19(7):e0306322.

PMID: 39052582 PMC: 11271891. DOI: 10.1371/journal.pone.0306322.

Glutathione in HIV-Associated Neurocognitive Disorders.

Erdos T, Masuda M, Venketaraman V Curr Issues Mol Biol. 2024; 46(6):5530-5549.

PMID: 38921002 PMC: 11202908. DOI: 10.3390/cimb46060330.

Mitochondrial DNA and Electron Transport Chain Protein Levels Are Altered in Peripheral Nerve Tissues from Donors with HIV Sensory Neuropathy: A Pilot Study.

Boustani A, Kulbe J, Andalibi M, Perez-Santiago J, Mehta S, Ellis R Int J Mol Sci. 2024; 25(9).

PMID: 38731951 PMC: 11083172. DOI: 10.3390/ijms25094732.

Molecular Role of HIV-1 Human Receptors (CCL5-CCR5 Axis) in neuroAIDS: A Systematic Review.

Silva M, Marinho R, Rodrigues Y, Brasil T, Dos Santos P, Silva C Microorganisms. 2024; 12(4).

PMID: 38674726 PMC: 11051963. DOI: 10.3390/microorganisms12040782.

References

Youle M, Osio M . A double-blind, parallel-group, placebo-controlled, multicentre study of acetyl L-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection. HIV Med. 2007; 8(4):241-50. DOI: 10.1111/j.1468-1293.2007.00467.x. View

Kallianpur A, Jia P, Ellis R, Zhao Z, Bloss C, Wen W . Genetic variation in iron metabolism is associated with neuropathic pain and pain severity in HIV-infected patients on antiretroviral therapy. PLoS One. 2014; 9(8):e103123. PMC: 4140681. DOI: 10.1371/journal.pone.0103123. View

Woldeamanuel Y, Kamerman P, Veliotes D, Phillips T, Asboe D, Boffito M . Development, Validation, and Field-Testing of an Instrument for Clinical Assessment of HIV-Associated Neuropathy and Neuropathic Pain in Resource-Restricted and Large Population Study Settings. PLoS One. 2016; 11(10):e0164994. PMC: 5072607. DOI: 10.1371/journal.pone.0164994. View

Holzinger E, Hulgan T, Ellis R, Samuels D, Ritchie M, Haas D . Mitochondrial DNA variation and HIV-associated sensory neuropathy in CHARTER. J Neurovirol. 2012; 18(6):511-20. PMC: 3587171. DOI: 10.1007/s13365-012-0133-y. View

Verma S, Estanislao L, Simpson D . HIV-associated neuropathic pain: epidemiology, pathophysiology and management. CNS Drugs. 2005; 19(4):325-34. DOI: 10.2165/00023210-200519040-00005. View

Berger A, Arezzo J, Schaumburg H, Skowron G, Merigan T, Bozzette S . 2',3'-dideoxycytidine (ddC) toxic neuropathy: a study of 52 patients. Neurology. 1993; 43(2):358-62. DOI: 10.1212/wnl.43.2.358. View

Smyth K, Affandi J, McArthur J, Bowtell-Harris C, Mijch A, Watson K . Prevalence of and risk factors for HIV-associated neuropathy in Melbourne, Australia 1993-2006. HIV Med. 2007; 8(6):367-73. DOI: 10.1111/j.1468-1293.2007.00478.x. View

Cherry C, Wadley A, Kamerman P . Diagnosing and treating HIV-associated sensory neuropathy: a global perspective. Pain Manag. 2016; 6(2):191-9. DOI: 10.2217/pmt.15.65. View

Estanislao L, Carter K, Mcarthur J, Olney R, Simpson D . A randomized controlled trial of 5% lidocaine gel for HIV-associated distal symmetric polyneuropathy. J Acquir Immune Defic Syndr. 2004; 37(5):1584-6. DOI: 10.1097/00126334-200412150-00010. View

10.

Sindrup S, Jensen T . Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain. 1999; 83(3):389-400. DOI: 10.1016/S0304-3959(99)00154-2. View

11.

Kohler J, Lewis W . A brief overview of mechanisms of mitochondrial toxicity from NRTIs. Environ Mol Mutagen. 2006; 48(3-4):166-72. DOI: 10.1002/em.20223. View

12.

Cornblath D, Chaudhry V, Carter K, Lee D, Seysedadr M, Miernicki M . Total neuropathy score: validation and reliability study. Neurology. 1999; 53(8):1660-4. DOI: 10.1212/wnl.53.8.1660. View

13.

Ciccosanti F, Corazzari M, Soldani F, Matarrese P, Pagliarini V, Iadevaia V . Proteomic analysis identifies prohibitin down-regulation as a crucial event in the mitochondrial damage observed in HIV-infected patients. Antivir Ther. 2010; 15(3):377-90. DOI: 10.3851/IMP1530. View

14.

Shlay J, Chaloner K, Max M, Flaws B, Reichelderfer P, Wentworth D . Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: a randomized controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. JAMA. 1998; 280(18):1590-5. DOI: 10.1001/jama.280.18.1590. View

15.

Lucas S, Nelson A . HIV and the spectrum of human disease. J Pathol. 2014; 235(2):229-41. DOI: 10.1002/path.4449. View

16.

Wulff E, Wang A, Simpson D . HIV-associated peripheral neuropathy: epidemiology, pathophysiology and treatment. Drugs. 2000; 59(6):1251-60. DOI: 10.2165/00003495-200059060-00005. View

17.

Keswani S, Polley M, Pardo C, Griffin J, McArthur J, Hoke A . Schwann cell chemokine receptors mediate HIV-1 gp120 toxicity to sensory neurons. Ann Neurol. 2003; 54(3):287-96. DOI: 10.1002/ana.10645. View

18.

Martin C, Solders G, Sonnerborg A, Hansson P . Painful and non-painful neuropathy in HIV-infected patients: an analysis of somatosensory nerve function. Eur J Pain. 2003; 7(1):23-31. DOI: 10.1016/s1090-3801(02)00053-8. View

19.

Simpson D, Rice A, Emir B, Landen J, Semel D, Chew M . A randomized, double-blind, placebo-controlled trial and open-label extension study to evaluate the efficacy and safety of pregabalin in the treatment of neuropathic pain associated with human immunodeficiency virus neuropathy. Pain. 2014; 155(10):1943-54. DOI: 10.1016/j.pain.2014.05.027. View

20.

Mullin S, Temu A, Kalluvya S, Grant A, Manji H . High prevalence of distal sensory polyneuropathy in antiretroviral-treated and untreated people with HIV in Tanzania. Trop Med Int Health. 2011; 16(10):1291-6. DOI: 10.1111/j.1365-3156.2011.02825.x. View